Global High and Medium Voltage Products Market to Reach $425.3 Billion by 2027

Project Details: - StrategyR - A Trademark of Global Industry Analysts, Inc. - Project Edition: 7. - Influencer Pool: 6204. - MarketGlass™ Platform - Our influencer driven interactive research platform draws from unique perspectives of participating executives from featured companies.

New York, March 30, 2021 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Global Gynaecological Cancer Drugs Industry" - https://www.reportlinker.com/p06041480/?utm_source=GNW
In addition to being a global intelligence exchange platform, MarketGlass™ is a powerful knowledge center that delivers dynamic project-focused market intelligence. Client companies will have complete insider access to the project Data stack.
- Interactive peer-to-peer and enterprise-to-enterprise ideation and market intelligence exchange is facilitated via a robust, secure, and validated process. The process draws from uniquely qualified project-specific and geographically focused executives overseeing business development, marketing and sales operations.

• Trends & Factors - Identifying and validating local trends and factors driving each competitive marketplace. These factors include pricing variances, market trajectories, Covid-19 impact and recovery, locally active leading brands, and other parameters impacting the region in the short to medium term such as supply chain realignments.

• Mobile Access & App - Our mobile version of the report may be accessed via our mobile app or directly for a full mobile experience.

• Complimentary Updates - for one year. At least one update in 12-month period is normal and anytime there’s a significant change affecting the market dynamics.

• Bespoke Updates & Team Collaborations - Clients may build a bespoke version of our report with peers on our MarketGlass™ platform which enables multidimensional data simulations.

• Knowledge Center - clients have full-stack data access for project data they support or purchase including primary research engagement stats, companies and executives.

Abstract:
- Global Gynaecological Cancer Drugs Market to Reach $36.9 Billion by 2027
- Amid the COVID-19 crisis, the global market for Gynaecological Cancer Drugs estimated at US$26.7 Billion in the year 2020, is projected to reach a revised size of US$36.9 Billion by 2027, growing at a CAGR of 4.8% over the analysis period 2020-2027. Alkylating Agent, one of the segments analyzed in the report, is projected to record a 4.3% CAGR and reach US$9.5 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Plant Alkaloid segment is readjusted to a revised 4% CAGR for the next 7-year period.
- The U.S. Market is Estimated at $7.9 Billion, While China is Forecast to Grow at 4.5% CAGR
- The Gynaecological Cancer Drugs market in the U.S. is estimated at US$7.9 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$6.5 Billion by the year 2027 trailing a CAGR of 4.5% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 4.6% and 3.8% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 4% CAGR.
- Anthracyclines Segment to Record 4.7% CAGR
- In the global Anthracyclines segment, USA, Canada, Japan, China and Europe will drive the 4.7% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$4.3 Billion in the year 2020 will reach a projected size of US$5.9 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$4.3 Billion by the year 2027.

- Select Competitors (Total 43 Featured) -

• AstraZeneca PLC

• Bristol-Myers Squibb Company

• Dr. Reddy’s Laboratories Ltd.

• Eli Lilly and Company

• F. Hoffmann-La Roche AG

• GlaxoSmithKline PLC

• Johnson & Johnson Services, Inc.

• Merck & Co., Inc.

• Pfizer, Inc.

• Sanofi SA

• Takeda Pharmaceutical Co., Ltd.

Read the full report: https://www.reportlinker.com/p06041480/?utm_source=GNW

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW
Influencer Market Insights
Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE
Table 1: World Current & Future Analysis for Gynaecological
Cancer Drugs by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 2: World Historic Review for Gynaecological Cancer Drugs
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 3: World 15-Year Perspective for Gynaecological Cancer
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets for Years 2012, 2020 & 2027

Table 4: World Current & Future Analysis for Alkylating Agent
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 5: World Historic Review for Alkylating Agent by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 6: World 15-Year Perspective for Alkylating Agent by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 7: World Current & Future Analysis for Plant Alkaloid by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 8: World Historic Review for Plant Alkaloid by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 9: World 15-Year Perspective for Plant Alkaloid by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 10: World Current & Future Analysis for Anthracyclines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 11: World Historic Review for Anthracyclines by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 12: World 15-Year Perspective for Anthracyclines by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 14: World Historic Review for Antitumor Antibiotic by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 15: World 15-Year Perspective for Antitumor Antibiotic by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 16: World Current & Future Analysis for Hospitals by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 17: World Historic Review for Hospitals by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 18: World 15-Year Perspective for Hospitals by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 19: World Current & Future Analysis for Clinics by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 20: World Historic Review for Clinics by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 21: World 15-Year Perspective for Clinics by Geographic
Region - Percentage Breakdown of Value Sales for USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World for Years
2012, 2020 & 2027

Table 22: World Current & Future Analysis for Specialized
Cancer Treatment Centers by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 23: World Historic Review for Specialized Cancer
Treatment Centers by Geographic Region - USA, Canada, Japan,
China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2012 through 2019 and % CAGR

Table 24: World 15-Year Perspective for Specialized Cancer
Treatment Centers by Geographic Region - Percentage Breakdown
of Value Sales for USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World for Years 2012, 2020 & 2027

Table 25: World Current & Future Analysis for Cervical Cancer
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 26: World Historic Review for Cervical Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 27: World 15-Year Perspective for Cervical Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 28: World Current & Future Analysis for Uterine Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 29: World Historic Review for Uterine Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 30: World 15-Year Perspective for Uterine Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 31: World Current & Future Analysis for Ovarian &
Fallopian Tube Cancer by Geographic Region - USA, Canada,
Japan, China, Europe, Asia-Pacific and Rest of World Markets -
Independent Analysis of Annual Sales in US$ Million for Years
2020 through 2027 and % CAGR

Table 32: World Historic Review for Ovarian & Fallopian Tube
Cancer by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 33: World 15-Year Perspective for Ovarian & Fallopian
Tube Cancer by Geographic Region - Percentage Breakdown of
Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific
and Rest of World for Years 2012, 2020 & 2027

Table 34: World Current & Future Analysis for Vulvar Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 35: World Historic Review for Vulvar Cancer by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 36: World 15-Year Perspective for Vulvar Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 37: World Current & Future Analysis for Vaginal Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 38: World Historic Review for Vaginal Cancer by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 39: World 15-Year Perspective for Vaginal Cancer by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 40: World Current & Future Analysis for Retail Pharmacies
by Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 41: World Historic Review for Retail Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 42: World 15-Year Perspective for Retail Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 43: World Current & Future Analysis for Hospital
Pharmacies by Geographic Region - USA, Canada, Japan, China,
Europe, Asia-Pacific and Rest of World Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2020 through
2027 and % CAGR

Table 44: World Historic Review for Hospital Pharmacies by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2012 through 2019 and
% CAGR

Table 45: World 15-Year Perspective for Hospital Pharmacies by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

Table 46: World Current & Future Analysis for e-Commerce by
Geographic Region - USA, Canada, Japan, China, Europe,
Asia-Pacific and Rest of World Markets - Independent Analysis
of Annual Sales in US$ Million for Years 2020 through 2027 and
% CAGR

Table 47: World Historic Review for e-Commerce by Geographic
Region - USA, Canada, Japan, China, Europe, Asia-Pacific and
Rest of World Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 48: World 15-Year Perspective for e-Commerce by
Geographic Region - Percentage Breakdown of Value Sales for
USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of
World for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

UNITED STATES
Table 49: USA Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 50: USA Historic Review for Gynaecological Cancer Drugs
by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 51: USA 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 52: USA Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 53: USA Historic Review for Gynaecological Cancer Drugs
by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 54: USA 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 55: USA Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 56: USA Historic Review for Gynaecological Cancer Drugs
by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and Retail
Pharmacies Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 57: USA 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 58: USA Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 59: USA Historic Review for Gynaecological Cancer Drugs
by Distribution Channel - Hospital Pharmacies and e-Commerce
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 60: USA 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

CANADA
Table 61: Canada Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 62: Canada Historic Review for Gynaecological Cancer
Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 63: Canada 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 64: Canada Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 65: Canada Historic Review for Gynaecological Cancer
Drugs by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 66: Canada 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 67: Canada Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 68: Canada Historic Review for Gynaecological Cancer
Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and
Retail Pharmacies Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 69: Canada 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 70: Canada Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 71: Canada Historic Review for Gynaecological Cancer
Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 72: Canada 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

JAPAN
Table 73: Japan Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 74: Japan Historic Review for Gynaecological Cancer Drugs
by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 75: Japan 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 76: Japan Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 77: Japan Historic Review for Gynaecological Cancer Drugs
by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 78: Japan 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 79: Japan Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 80: Japan Historic Review for Gynaecological Cancer Drugs
by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and Retail
Pharmacies Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 81: Japan 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 82: Japan Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 83: Japan Historic Review for Gynaecological Cancer Drugs
by Distribution Channel - Hospital Pharmacies and e-Commerce
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 84: Japan 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

CHINA
Table 85: China Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 86: China Historic Review for Gynaecological Cancer Drugs
by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 87: China 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 88: China Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 89: China Historic Review for Gynaecological Cancer Drugs
by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 90: China 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 91: China Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 92: China Historic Review for Gynaecological Cancer Drugs
by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and Retail
Pharmacies Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 93: China 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 94: China Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 95: China Historic Review for Gynaecological Cancer Drugs
by Distribution Channel - Hospital Pharmacies and e-Commerce
Markets - Independent Analysis of Annual Sales in US$ Million
for Years 2012 through 2019 and % CAGR

Table 96: China 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

EUROPE
Table 97: Europe Current & Future Analysis for Gynaecological
Cancer Drugs by Geographic Region - France, Germany, Italy, UK
and Rest of Europe Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2020 through 2027 and % CAGR

Table 98: Europe Historic Review for Gynaecological Cancer
Drugs by Geographic Region - France, Germany, Italy, UK and
Rest of Europe Markets - Independent Analysis of Annual Sales
in US$ Million for Years 2012 through 2019 and % CAGR

Table 99: Europe 15-Year Perspective for Gynaecological Cancer
Drugs by Geographic Region - Percentage Breakdown of Value
Sales for France, Germany, Italy, UK and Rest of Europe Markets
for Years 2012, 2020 & 2027

Table 100: Europe Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 101: Europe Historic Review for Gynaecological Cancer
Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 102: Europe 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 103: Europe Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 104: Europe Historic Review for Gynaecological Cancer
Drugs by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 105: Europe 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 106: Europe Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 107: Europe Historic Review for Gynaecological Cancer
Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and
Retail Pharmacies Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 108: Europe 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 109: Europe Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 110: Europe Historic Review for Gynaecological Cancer
Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 111: Europe 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

FRANCE
Table 112: France Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 113: France Historic Review for Gynaecological Cancer
Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 114: France 15-Year Perspective for Gynaecological Cancer
Drugs by Drug Class - Percentage Breakdown of Value Sales for
Alkylating Agent, Plant Alkaloid, Anthracyclines and Antitumor
Antibiotic for the Years 2012, 2020 & 2027

Table 115: France Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 116: France Historic Review for Gynaecological Cancer
Drugs by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 117: France 15-Year Perspective for Gynaecological Cancer
Drugs by End-Use - Percentage Breakdown of Value Sales for
Hospitals, Clinics and Specialized Cancer Treatment Centers for
the Years 2012, 2020 & 2027

Table 118: France Current & Future Analysis for Gynaecological
Cancer Drugs by Indication - Cervical Cancer, Uterine Cancer,
Ovarian & Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer
and Retail Pharmacies - Independent Analysis of Annual Sales in
US$ Million for the Years 2020 through 2027 and % CAGR

Table 119: France Historic Review for Gynaecological Cancer
Drugs by Indication - Cervical Cancer, Uterine Cancer, Ovarian &
Fallopian Tube Cancer, Vulvar Cancer, Vaginal Cancer and
Retail Pharmacies Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 120: France 15-Year Perspective for Gynaecological Cancer
Drugs by Indication - Percentage Breakdown of Value Sales for
Cervical Cancer, Uterine Cancer, Ovarian & Fallopian Tube
Cancer, Vulvar Cancer, Vaginal Cancer and Retail Pharmacies for
the Years 2012, 2020 & 2027

Table 121: France Current & Future Analysis for Gynaecological
Cancer Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce - Independent Analysis of Annual Sales in US$
Million for the Years 2020 through 2027 and % CAGR

Table 122: France Historic Review for Gynaecological Cancer
Drugs by Distribution Channel - Hospital Pharmacies and
e-Commerce Markets - Independent Analysis of Annual Sales in
US$ Million for Years 2012 through 2019 and % CAGR

Table 123: France 15-Year Perspective for Gynaecological Cancer
Drugs by Distribution Channel - Percentage Breakdown of Value
Sales for Hospital Pharmacies and e-Commerce for the Years
2012, 2020 & 2027

GERMANY
Table 124: Germany Current & Future Analysis for Gynaecological
Cancer Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic - Independent Analysis
of Annual Sales in US$ Million for the Years 2020 through 2027
and % CAGR

Table 125: Germany Historic Review for Gynaecological Cancer
Drugs by Drug Class - Alkylating Agent, Plant Alkaloid,
Anthracyclines and Antitumor Antibiotic Markets - Independent
Analysis of Annual Sales in US$ Million for Years 2012 through
2019 and % CAGR

Table 126: Germany 15-Year Perspective for Gynaecological
Cancer Drugs by Drug Class - Percentage Breakdown of Value
Sales for Alkylating Agent, Plant Alkaloid, Anthracyclines and
Antitumor Antibiotic for the Years 2012, 2020 & 2027

Table 127: Germany Current & Future Analysis for Gynaecological
Cancer Drugs by End-Use - Hospitals, Clinics and Specialized
Cancer Treatment Centers - Independent Analysis of Annual Sales
in US$ Million for the Years 2020 through 2027 and % CAGR

Table 128: Germany Historic Review for Gynaecological Cancer
Drugs by End-Use - Hospitals, Clinics and Specialized Cancer
Treatment Centers Markets - Independent Analysis of Annual
Sales in US$ Million for Years 2012 through 2019 and % CAGR

Table 129: Germany 15-Year Perspective for Gynaecological
Cancer Drugs by End-Use - Percentage Breakdown of Value Sales

Please contact our Customer Support Center to get the complete Table of Contents
Read the full report: https://www.reportlinker.com/p06041480/?utm_source=GNW

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

CONTACT: Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001